¼¼°èÀÇ ½ÉÀåÁúȯ ¹× ½Å°æ¿ë IVD ½ÃÀå : Á¦Ç° À¯Çüº°, ±â¼úº°, ÃÖÁ¾ ¿ëµµº° - ¿¹Ãø(2024-2032³â)
IVD in Cardiology and Neurology Market - By Product Type (Instruments, Reagents, Kits & Consumables, Software & Services), Technology (Immunoassays, Molecular Diagnostics, Hematology), End-use (Hospitals, Clinics) - Global Forecast (2024 - 2032)
»óǰÄÚµå : 1516078
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 176 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,644,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,289,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,440,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÉÀå ¹× ½Å°æ¿ë IVD ½ÃÀå ±Ô¸ð´Â ½ÉÇ÷°ü ¹× ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î 2024³âºÎÅÍ 2032³â±îÁö 5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

WHO¿¡ µû¸£¸é, ½ÉÇ÷°ü Áúȯ(CVDs)Àº Àü ¼¼°è ÁÖ¿ä »ç¸Á ¿øÀÎÀ¸·Î ¸Å³â ¾à 1,790¸¸ ¸íÀÇ ¸ñ¼ûÀ» ¾Ñ¾Æ°¡°í ÀÖ½À´Ï´Ù. ½ÉÀ庴°ú ³úÁ¹ÁßÀÌ ¿©ÀüÈ÷ ÁÖ¿ä »ç¸Á ¿øÀÎÀ¸·Î ²ÅÈ÷¸é¼­ Á¶±â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿, ºÐÀÚÁø´Ü, ÇöÀå °Ë»ç µî IVD ±â¼úÀº ÀÌ·¯ÇÑ Áúº´À» Àû½Ã¿¡ ¹ß°ß, ¸ð´ÏÅ͸µ ¹× °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

ºü¸¥ ±â¼ú Çõ½Å°ú ÀÇ·áºñ ÁöÃâ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì, µðÁöÅÐ º´¸®ÇÐ, AI ±â¹Ý Áø´Ü µµ±¸¿Í °°Àº »õ·Î¿î Áø´Ü Ç÷§ÆûÀÇ °³¹ßÀº °Ë»çÀÇ Á¤È®¼º°ú À¯È¿¼ºÀ» Çâ»ó½ÃÄÑ ÀÓ»ó ÇöÀå¿¡¼­ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù. ½ÅÈï±¹À» Áß½ÉÀ¸·Î ÇÑ ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ´Â °í±Þ Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» È®´ëÇÒ °ÍÀÔ´Ï´Ù.

½ÉÀåÁúȯ ¹× ½Å°æ¿ë IVD »ê¾÷Àº Á¦Ç° À¯Çü, ±â¼ú, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â Á¤È®¼º, È¿À²¼º, Áø´Ü ÀýÂ÷ÀÇ ÅëÇÕÀ» ÁöÁöÇÏ´Â ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ºÐ¾ß ½ÃÀå Á¡À¯À²ÀÌ 2032³â±îÁö Å« ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÷´Ü ¼ÒÇÁÆ®¿þ¾î´Â º¹ÀâÇÑ Áø´Ü µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ¿© Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ È¯ÀÚ Ä¡·á °áÁ¤À» ³»¸®°í ÀýÂ÷¸¦ ÀÚµ¿È­Çϰí È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ °ü¸®, ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ¿ø°Ý ÀÇ·á¿Í °°Àº ¼­ºñ½ºµµ ƯÈ÷ ¸¸¼º ½ÉÇ÷°ü ¹× ½Å°æ°è ÁúȯÀÇ È®»êÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

Ç÷¾×ÇÐ ±â¼ú ºÐ¾ßÀÇ ½ÉÀå ¹× ½Å°æ IVD »ê¾÷Àº Ç÷¾× °ü·Ã ¸Å°³ º¯¼ö¿¡ ´ëÇÑ Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÏ·Á´Â °­·ÂÇÑ ¿ä±¸¿¡ ÈûÀÔ¾î 2024-2032³â »çÀÌ¿¡ »ó´çÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀüÇ÷±¸¼öÄ¡(CBC) ¹× ÀÀ°í ÇÁ·ÎÆÄÀϰú °°Àº Ç÷¾×ÇÐ °Ë»ç´Â ºóÇ÷, ÀÀ°í Àå¾Ö, ½ÉÀå ¹× ³ú °Ç°­¿¡ ½É°¢ÇÑ ¿µÇâÀ» ¹ÌÄ¡´Â Áúȯ°ú °°Àº »óŸ¦ °¨ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â À§Çè ¿äÀÎÀ» Æò°¡Çϰí, Áúº´ÀÇ ÁøÇàÀ» °Ë»çÇϰí, Ä¡·á ¼ö´ÜÀÇ È¿°ú¸¦ ÃßÁ¤ÇÏ´Â µ¥¿¡µµ Áß¿äÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå ¹× ½Å°æ IVD »ê¾÷Àº ½Å°æ ¹× ½ÉÇ÷°ü Áúȯ Áõ°¡·Î ÀÎÇØ 2024³âºÎÅÍ 2032³â±îÁö ¿Ï¸¸ÇÑ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±Þ¼ÓÇÑ µµ½ÃÈ­¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­·Î ÀÎÇØ ³úÁ¹Áß, Ä¡¸Å, °ü»óµ¿¸Æ¼º ½ÉÀåÁúȯ°ú °°Àº Áúº´ÀÇ ¹ßº´·üÀÌ ±ÞÁõÇϸ鼭 ÷´Ü Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ ¿©·¯ Á¤ºÎ°¡ ÀÇ·á ÀÎÇÁ¶ó¿¡ ¸¹Àº ÅõÀÚ¸¦ ÇÏ°í °øÁߺ¸°ÇÀ» À§ÇÑ ³ë·ÂÀ» ÅëÇØ Á¶±â Áø´ÜÀ» Àå·ÁÇϰí ÀÖ´Â °Íµµ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Á¦Ç° À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ±â¼úº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦9Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

IVD in cardiology and neurology market size is projected to record 5% CAGR between 2024 and 2032, driven by the rising prevalence of cardiovascular and neurological diseases. As per WHO, cardiovascular diseases (CVDs) are the major cause of death worldwide, claiming around 17.9 million lives every year. As heart diseases and strokes continue to be the leading causes of death, the demand for early and accurate diagnostic tools is increasing. IVD technologies, such as biomarkers, molecular diagnostics, and point-of-care testing provide critical information for the timely detection, monitoring, and management of these conditions.

Rapid technological innovations and increasing healthcare expenditures will also influence the market growth. The development of new diagnostic platforms, such as next-generation sequencing, digital pathology, and AI-based diagnostic tools will improve the accuracy and efficacy of tests, making them indispensable in clinical settings. Investments in healthcare infrastructure, specifically in emerging economies, will also improve access to advanced diagnostic services, expanding the market growth.

The IVD in cardiology and neurology industry is segmented into product type, technology, end-use and region.

Based on product type, the market share from the software & services segment is poised to generate substantial revenue by 2032, favored their accuracy, efficiency, and integration of diagnostic procedures. Advanced software enables analysis of complex diagnostic data for accurate and timely patient care decisions while automating procedures and improving efficiency. Services, such as data management, remote monitoring and telemedicine are also becoming increasingly important, especially due to the prevalence of chronic cardiovascular and neurological diseases.

IVD in cardiology and neurology industry from the hematology technology segment is slated to witness decent growth during 2024-2032, led by the strong need for providing crucial insights into blood-related parameters. Hematology tests, such as complete blood count (CBC) and coagulation profiles help detect conditions like anemia, clotting disorders, and diseases that can seriously affect heart and brain health. These tests are also important to assess risk factors, examine the progression of the disease and estimate the effectiveness of treatment measures.

Asia Pacific IVD in cardiology and neurology industry is anticipated to expand at a modest rate over 2024-2032, attributed to the increasing burden of neurological and cardiovascular diseases. Rapid urbanization and lifestyle changes have surged the incidence of diseases, such as strokes, dementia, and coronary heart disease, further increasing the demand for advanced diagnostic solutions. Multiple governments in the region are also investing significantly in health infrastructure and promoting early diagnosis through public health initiatives, stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â